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Abstract. Differentiating dementia with Lewy bodies (DLB) from Alzheimer’s Disease (AD) can be difficult because
of the substantial overlap in clinical features. Since deficits in serotonergic and dopaminergic pathways seem more pro-
nounced in DLB patients, we investigated whether cerebrospinal fluid (CSF) analysis of neurotransmitter metabolites, in
addition to brain-specific proteins, may improve the differentiation between DLB and AD. We retrospectively compared CSF
concentrations of the neurotransmitter metabolites homovanillic acid (HVA), 5-hydroxyindolacetic acid (5-HIAA), and 3-
methoxy-4-hydroxyphenylethyleneglycol (MHPG) and the brain-specific proteins total tau (t-tau), phosphorylated tau protein
(p-tau), and amyloid-42 (A42) in 45 patients with AD (mean age 71.6 years; 34 (76%) men; 44 probable AD, 1 definite) and
23 patients with DLB (mean age 71.6 years; 18 (78%) men; 6 possible DLB, 16 probable, 1 definite). The concentrations of
all neurotransmitter metabolites, as well as those for t-tau and p-tau protein, were significantly lower in DLB compared to AD,
irrespective of the diagnostic certainty (i.e., possible or probable). The currently used combination of A42, p-tau, and t-tau
yielded a sensitivity of 92.9% and a specificity of 90%. The addition of MHPG resulted in an increased sensitivity of 97.6%
and a specificity of 95% for the discrimination between DLB and AD. In conclusion, the combination of MHPG and the brain
specific proteins t-tau, p-tau, and A42 in CSF were associated with the clinical diagnosis of DLB and discriminated between
AD and DLB with high diagnostic accuracy, suggesting this combination as a potential biomarker for DLB.
Keywords: Alzheimer’s disease, amyloid-, cerebrospinal fluid, dementia with Lewy bodies, diagnosis, MHPG, neurotransmitter
metabolites, tau
INTRODUCTION
Dementia with Lewy bodies (DLB) is a common
cause of dementia, accounting for up to 20% of the
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dementia population [1]. Core features include fluctu-
ating cognition, visual hallucinations, autonomic dis-
turbances, and parkinsonism. The neuropathological
hallmark is the ‘Lewy body’, an intraneuronal inclu-
sion body consisting of, among others, ubiquitin and
-synuclein, present in the substantia nigra and neo-
cortex as well as limbic and forebrain structures [2, 3].
Differentiation between DLB and Alzheimer’s dis-
ease (AD) on clinical grounds alone can be difficult
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due to substantial overlap in clinical presentation, as
reflected by low sensitivity of the clinical criteria for
DLB [2, 4, 5]. However, early recognition is impor-
tant because of the therapeutic consequences. DLB
patients show great sensitivity to neuroleptics, which
may cause physical and cognitive deterioration, and
even increased mortality [6–8]. Hence, biomarkers that
improve the early recognition of DLB are urgently
needed.
Currently the cerebrospinal fluid (CSF) concentra-
tions of amyloid-42 (A42), total tau protein (t-tau),
and tau protein phosphorylated at Thr181 (p-tau) are
employed to identify (incipient) AD patients among
patients with dementia syndromes or MCI [9]. How-
ever, the differentiation between the different dementia
syndromes based on CSF analysis is limited, e.g.,
because of considerable overlap between AD and DLB
[10–16].
Deficits in serotonergic and dopaminergic pathways,
associated with symptoms of autonomic dysfunc-
tion or parkinsonism, are more pronounced in DLB
patients compared to AD patients [17–20]. We
anticipated that CSF concentrations of the neuro-
transmitter metabolites homovanillic acid (HVA), 5-
hydroxyindolacetic acid (5-HIAA), and 3-methoxy-4-
hydroxyphenylethyleneglycol (MHPG), the catabolic
end-products of dopamine and epinephrine degrada-
tion, are lower in DLB than in AD [21–24]. Therefore,
we aimed to investigate the additional diagnostic value
of CSF neurotransmitter metabolites compared to CSF
brain-specific proteins in differentiating between DLB
and AD.
MATERIALS AND METHODS
Patients
We included consecutive patients with a clini-
cal diagnosis of DLB who were referred to either
the movement disorder clinic of the Department of
Neurology or the memory clinic of the Department
of Geriatric Medicine at the Radboud University
Nijmegen Medical Centre to cover the broad clinical
spectrum of DLB, who underwent a lumbar punc-
ture between December 2003 and June 2008 as part
of the diagnostic work-up (Fig. 1). The concentra-
tion of MHPG in CSF is independent of the fraction,
however, since the concentrations of the neurotrans-
mitter metabolites HVA and 5-HIAA do depend on
the CSF fraction [25], only patients with separate col-
lection of the 8th–10th (±2) milliliter fraction were
included for analysis. Diagnostic evaluation included a
detailed medical history, systematic physical and neu-
rological examination, routine laboratory testing, and a
brain MRI scan. Cognitive function was assessed using
the Mini Mental State Examination (MMSE) [26].
Additionally, 15 DLB patients underwent neuropsy-
chological assessment. Symptoms of parkinsonism
were assessed using the Hoehn and Yahr score. Hetero-
anamnesis was employed to assess the presence of
visual hallucinations and fluctuations in cognition. The
clinical diagnosis was established by either a special-
ized neurologist or geriatrician.
Out of 93 eligible AD patients from the memory
clinic database, an age and gender matched group
of 45 AD patients was randomly drawn. The clini-
cal diagnosis of these patients was established by a
multidisciplinary team consisting of a geriatrician, a
neurologist, and a neuropsychologist.
In April 2010 a single rater (MBA) reassessed the
final clinical diagnosis by clinical chart review in order
to improve diagnostic certainty. Reassessment of the
clinical diagnosis was performed after a follow-up
period of 12 months or longer (Table 1) according to
the international consensus criteria for DLB [27] and
AD [28]. The use of medication (serotonergic as well as
dopaminergic medication), the presence of white mat-
ter lesions and the presence of behavioral disorders,
hallucinations, and symptoms of autonomic dysfunc-
tion were recorded to enable subgroup analysis. The
IRB has approved of this study which was conducted
according to the Helsinki Declaration.
CSF parameters
CSF samples were collected in polypropylene tubes,
centrifuged, aliquoted, and stored at −80◦C until anal-
ysis. We aimed for separate collection of the 8th–10th
ml (±2) fraction for analysis of neurotransmitter
metabolites. The following CSF variables were taken
into account for the present study: A42, t-tau, p-tau,
MHPG, 5-HIAA, and HVA; all parameters were ana-
lyzed within 4 weeks after CSF collection.
The methods of analysis of A42, t-tau, p-tau,
MHPG, HVA, and 5-HIAA in CSF, their validation
and reference values have been previously described
[25, 29, 30].
Statistical analysis
Between-groups analysis was performed using the
Student’s t-test in case of normally distributed data.
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Fig. 1. Flowchart of patient inclusion in this study. AD: Alzheimer’s disease, DLB: dementia with Lewy Bodies, CSF: cerebrospinal fluid, N:
number. CSF was obtained during the initial diagnostic assessment upon presentation.
Non-Gaussian distributed data were analyzed using
the Mann-Whitney test. Pearson correlation coefficient
was used to analyze correlations. Prior to corre-
lation analysis, non-Gaussian distributed data were
log-transformed to meet assumptions of normality and
homogeneity. Logistic regression analysis was used to
analyze relations between categorical variables.
Multivariate logistic regression and receiver opera-
tor characteristic (ROC) analysis were used to evaluate
the diagnostic value of CSF parameters. Statistical
analysis was carried out using GraphPad Prism ver-
sion 4 (San Diego, CA) and SPSS software version
16.0 (Chicago, IL).
RESULTS
Patients
At the time of the clinical chart review, 23 patients
fulfilled the diagnostic criteria for DLB (6 possible
DLB, 16 probable DLB, and 1 definite DLB) and 45
patients fulfilled the diagnostic criteria of AD (44 prob-
able AD, and 1 definite AD). None of the patients
complied with the criteria for mild cognitive impair-
ment (MCI) [38]. Demographic characteristics are
shown in Table 1. Six DLB patients and two AD
patients had deceased at the time of the chart review.
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Table 1
Characteristics of the diagnostic groups
Demographic characteristics DLB AD p-valueb
Number of patients 23 45
Age, ya 71.6 (9.3) 71.6 (9.4) NS (p = 0.89)
Number of men (%) 18 (78) 34 (76) NS (p = 0.88)
Disease duration, monthsa 38.8 (26.4) 33.0 (28.1) NS (p = 0.42)
Cognitive function, MMSEa 23.0 (4.2) 19.5 (5.3) <0.05
Duration of follow up, months 55.9 (30.3) 49.7 (32.4) NS (p = 0.75)
Vascular co-morbidity (%)a 5 (22) 12 (27) NS (p = 0.73)
Autonomic dysfunction (%)a 13 (76.5) 9 (20.5) <0.001
Orthostatic hypotension (%) 2/(11.8) 1 (2.3) <0.001
Urogenital dysfunction (%) 11 (64.7) 8 (18.2) <0.001
Hallucinations (%)a 13 (57) 1 (2) <0.001
Use of SSRI (%)a 4 (17) 3 (7) NS (p = 0.15)
Use of L-dopa (%)a 6 (26) 0 (0) <0.001
Severity of parkinsonism, H&Y scorea 2.5 (2.0–2.5) NA NA
CSF fraction analyzed, ml (lower margin)c 8.0 (7.0–9.0) 7.3 (6.8–8.0) NS (p = 0.18)
CSF fraction analyzed, ml (upper margin)c 11.0 (10.0–11.5) 10.0 (9.0–10.5) <0.05
Data represent mean and standard deviation (in case of Gaussian distribution), median and interquartile range (in
case of non- Gaussian distribution) or number and percentage. a At the time of lumbar puncture. b P value for dif-
ferences using student’s T-test. Gender distribution, the presence of vascular comorbidity, autonomic dysfunction,
hallucinations and the use of medication were analyzed using χ2 test. C for neurotransmitter metabolite analysis
DLB: dementia with Lewy bodies; AD: Alzheimer’s disease; MMSE: mini mental state examination; SSRI: selec-
tive serotonine reuptake inhibitor; L-dopa: levodopa; H&Y score: Hoehn and Yahr score; NA: not applicable; CSF:
cerebrospinal fluid.
The initial diagnoses, prior to CSF analysis were
possible AD (n = 18), probable AD (n = 19), cognitive
disorder not further specified (n = 6), Creutzfeldt-
Jakob disease (n = 1) and possible DLB (n = 1) for
the AD patients; and for the DLB patients: possi-
ble DLB (n = 10), possible AD (n = 3), Parkinson’s
disease (n = 5), corticobasal degeneration (n = 1),
multiple system atrophy (n = 1), cerebral small ves-
sel disease (n = 2) and psychogenic complaints
(n = 1).
Disease duration, gender, and age at the time of lum-
bar puncture were similar in AD and DLB. MMSE
score was lower in AD (p < 0.05). Six DLB patients,
and none of the AD patients, used dopaminergic ther-
apy (median 375 mg; range 62.5–800 mg L-dopa/day).
CSF parameters
The results of the CSF analysis are presented in
Fig. 2. The concentrations of 5-HIAA (p < 0.01), HVA
Fig. 2. Scatterplots of the CSF concentrations of (A) 5-HIAA (nM), (B) HVA (nM), (C) MHPG (nM), (D) T-Tau (ng/L), (E) A42 (ng/L) and
(F) P-Tau (ng/L) in DLB and AD subgroups. Horizontal lines represent median levels.
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Table 2
ROC-analysis of CSF parameters in DLB vs. AD
CSF Number of Cut-off Sensitivity Specificity Area under the Youden Likelihood
variables patientsa point (%) (%) curve (95% CI) indexb ratioc
Univariate analysis
5-HIAA (nM) DLB n = 22, AD n = 43 <92.5 72.1 68.2 0.72 (0.58–0.86) 0.39 2.10
MHPG (nM) DLB n = 22, AD n = 43 <44.5 74.4 78.3 0.81 (0.68–0.92) 0.53 4.43
HVA (nM) DLB n = 22, AD n = 43 <182.0 76.2 70.0 0.69 (0.54–0.85) 0.46 2.54
A42 (ng/L) DLB n = 21, AD n = 44 >482.0 62.0 65.0 0.65 (0.49–0.81) 0.27 1.78
P-tau (ng/L) DLB n = 21, AD n = 44 <67.0 81.0 95.0 0.92 (0.86–0.99) 0.76 16.19
T-tau (ng/L) DLB n = 20, AD n = 44 <294 90.4 90.0 0.95 (0.91–1.0) 0.80 9.05
Multivariate analysis
Model 1d DLB n = 22, AD n = 42 >0.42 92.9 90.0 0.96 (0.92–1.0) 0.82
Model 2e DLB n = 22, AD n = 44 >−0.455 97.6 95.0 0.99 (0.97–1.0) 0.93 39.6
a Due to missing data points, not all CSF parameters were available in all patients. b Youden index: sensitivity + specificity – 1.0 cLikelihood
ratio: sensitivity/(1-specificity) d y = −5.098 + 0.005 × p-tau, +0.020 × t-tau – 0.002 × A42. AUC: 0.96 (0.92–1.0) e y = −13.965 + 0.072 × p-
tau, +0.021 × t-tau + 0.143 × MHPG – 0.006 × A42. AUC: 0.99 (0.97–1,0)ROC-: receiver operating characteristic; DLB: dementia with Lewy
bodies; AD: Alzheimer’s disease; CSF: cerebrospinal fluid; 5-HIAA: 5-hydroxyindolacetic acid; HVA: homovanillic acid; MHPG: 3-methoxy-
4-hydroxyphenylethyleneglycol; A42: amyloid 42; p-tau: phospho-tau; t-tau: total tau protein; 95 CI: 95% confidence interval.
Fig. 3. ROC curves of the models 1 and 2 Model 1:
y = −5.098 + 0.005×p-tau, +0.020×t-tau – 0.002×A42. AUC:
0.96 (0.92–1.0) Model 2: y = −13.965 + 0.072×p-tau, +0.021×t-
tau + 0.143×MHPG – 0.006×A42. AUC: 0.99 (0.97–1.0).
(p < 0.05), and especially MHPG, t-tau, and p-tau (all
p < 0.0001) were lower in DLB as compared to AD
whereas the A42 concentrations tended to be higher
in DLB than in AD (p = 0.06). We did not find an
increase in median MHPG (p = 0.53) or HVA concen-
trations (p = 0.43) in DLB patients using dopaminergic
medication relative to naı¨ve DLB patients, hence these
patients were not excluded from further data analysis.
Compared to our reference values, 72.7% of AD
patients had a decreased CSF A42 (≤500 ng/l) as
opposed to 45.5% of DLB patients (p < 0.05). CSF t-tau
was increased (≥350 ng/l) in 13.6% of DLB patients,
compared to 84.1% of AD patients, whereas p-tau was
increased (≥85 ng/l) in 0% of the DLB patients as
opposed to 70.5% of the AD patients (all p < 0.0001).
The above described differences in CSF parameters
were present in AD and DLB patients irrespective of
the certainty of diagnosis (i.e., possible or probable).
We demonstrated no association between the occur-
rence of behavioral problems, use of serotonergic
medication, presence of white matter lesions on MRI
or symptoms of autonomic dysfunction on one hand,
and levels of the three neurotransmitter metabolites and
brain-specific proteins t-tau, p-tau, or A42 on the other
hand, neither in the entire group, nor in the DLB and
AD patient groups separately. However, hallucinations
were associated with lower MHPG (odds ratio (OR)
4.8, 95% CI 1.3–17.2, p < 0.001) and HVA (OR 6.6,
95% CI 1.5–28.6, p < 0.001) in DLB patients.
Repeating the analyses while adjusting for age, dis-
ease duration, and cognitive function did not markedly
change our results.
Diagnostic accuracy
Univariate logistic regression analysis (carried out
to discriminate DLB from AD) revealed that the sen-
sitivity and specificity exceeded 80% for both t-tau
and p-tau (Table 2). To assess the diagnostic value of
neurotransmitter metabolites over the currently used
combination of t-tau, p-tau, and A42, we performed
multivariate logistic regression analysis using block
entry regression.
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The first block consisted of the the currently
used brain specific proteins resulting in a Nagelk-
erke R2 of 0.77 (p < 0.001, model χ2(3) = 49.8). In
the second block MHPG, HVA, and 5-HIAA were
added. Only MHPG showed significant added value
to the constructed model based on block 1, improv-
ing Nagelkerke R2 from 0.77 to 0.87 (p < 0.001, model
χ2(4) = 59.4). ROC-curve analysis of the first model
(based on t-tau, p-tau, and A42 demonstrated a sensi-
tivity of 92.9% and a specificity of 90% (AUC 0.96).
The subsequent addition of MHPG resulted in further
improvement of the diagnostic accuracy with a sensi-
tivity of 97.6% and a specificity of 95% (AUC 0.99).
DISCUSSION
We found that CSF concentrations of 5-HIAA, HVA,
MHPG, t-tau, and p-tau were significantly lower in
DLB than in AD, whereas CSF A42 tended to be
higher in DLB. Most important, the combination of
MHPG, p-tau, t-tau, and A42 analysis discriminated
between AD and DLB with high diagnostic accuracy.
We are the first to rigorously investigate CSF MHPG
in a large group of DLB patients. Only one earlier
study examined CSF MHPG concentrations in DLB
and, although the sample size was small (n = 8 sub-
jects), findings are consistent with ours [22]. Moreover,
our findings of lower concentrations of CSF MHPG
are consistent with previous neuropathological stud-
ies, demonstrating degeneration of the locus coeruleus
[31] and decreased concentrations of norepinephrine
in putamen and neocortex, as compared to controls
and AD patients [32]. Moreover, these findings are
also compatible with the neuropathologically observed
degeneration of nigrostriatal dopaminergic neurons in
DLB [33], because reduced availability of dopamine
results in a decrease of dopamine-derived neurotrans-
mitter metabolites.
Interestingly, even though 5-HIAA and HVA were
significantly lower in DLB as compared to AD, both
did not contribute significantly to the constructed
model, possibly because the direction of the effects
were similar to MHPG and the strong correlation
between CSF HVA and MHPG r 0.618, p < 0.001.
The brain specific proteins t-tau, p-tau, and A42
have been studied abundantly in both AD and DLB.
We confirmed previous results that CSF A42 concen-
trations are low in DLB and close to the levels observed
in AD patients [10–16], possibly reflecting the AD-
like pathology observed in a proportion of the DLB
patient upon postmortem examination, substantially
limiting its discriminating properties. We also found
increased t-tau levels in AD, but generally normal lev-
els in DLB. Previous studies demonstrated conflicting
results; some studies found elevated t-tau concentra-
tions in DLB patients [14, 15], whereas other studies
showed normal t-tau concentrations [10, 16, 37], as we
did. In our study, as in two other reports [34, 37], p-tau
concentrations were normal in DLB, although conflict-
ing results were also reported [35]. These discrepancies
underscore the importance of additional CSF param-
eters, in order to compose a more comprehensive and
robust CSF profile.
Our results imply that the addition of CSF MHPG
to the currently used analysis of brain-specific pro-
teins can further improve the diagnostic differentiation
between DLB and AD. The recent observation that up
to 18% of patients suffering from dementia are treated
with neuroleptics [36] further stresses the importance
of diagnostic accuracy in early disease stages, because
the use of neuroleptics in DLB patients is contraindi-
cated for fear of increased physical and cognitive
deterioration, as well as increased mortality [39].
Assessment of cognitive dysfunction is often per-
formed by using the MMSE score. This score, however,
has certain disadvantages, as it is an inaccurad method
of cognitive assessment. For example, it is known that,
as cognition is known to fluctuate in DLB, test–re-test
variability is substantial. However, the MMSE is easy
to perform and still the most commonly used cognitive
screening assessment in daily practice, and therefore
used in this study as well. The slightly lower MMSE
scores in the AD subgroup might reflect the often
more pronounced amnestic and orientation problems
observed in AD.
This difference in MMSE likely does not affect
the results for CSF t-tau, p-tau and A42, since it is
known that CSF biomarker levels are hardly depen-
dent on disease state and severity, especially in AD.
It is, however, unknown whether this also applies to
DLB and to CSF neurotransmitter metabolite levels.
Therefore, to acknowledge these differences in MMSE
score, but also in age and gender, between AD and DLB
we included these parameters in our models, but this
modification did not resulted in an altered AUC.
This study has several potential drawbacks. First,
the retrospective design may have introduced selection
bias. Only DLB and AD patients who underwent a lum-
bar puncture as part of their diagnostic workup were
included in this study, possibly leading to selection
of more atypical phenotypes. However, we included
a substantial number of probable and even definite
DLB patients, who showed similar CSF patterns.
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Second, the clinical diagnosis was not confirmed neu-
ropathologically in most patients. Misclassification
may therefore have occurred. However, accuracy of
the final clinical diagnosis was optimized using the
following approach: thorough clinical and ancillary
investigations at baseline; extensive follow-up (53
months for DLB and 50 months for AD patients)
to monitor disease progression and development of
new diagnostic signs; and establishing the diagnosis
according to international consensus criteria in a spe-
cialized clinic. Third, the proposed model based on
CSF biomarkers warrants validation in an independent
and larger cohort. Despite these drawbacks, our results
underline the importance of CSF analysis for the dif-
ferentiation between dementia syndromes, specifically
between AD and DLB. Moreover the addition of CSF
MHPG to the currently used analysis of the brain-
specific proteins t-tau, p-tau, and A42 may further
improve this diagnostic differentiation. These results
warrant validation in a prospective study with prefer-
ably neuropathological confirmation of the diagnosis
and inclusion of patients with other types of dementia.
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